Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-817, and SPN-820. The company's technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). The company majority customers include pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.
Headquarters
United States of America
Address
9715 Key West Avenue, Rockville, Maryland, 20850
Website
www.supernus.com
Telephone
1 301 8382500
No of Employees
612
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
SUPN (NASD)
Revenue (2022)
$667.2M
15.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
13.6%
(2022 vs 2021)
Market Cap*
$1.9B
Net Profit Margin (2022)
XYZ
-1.2%
(2022 vs 2021)
* As of and is in US$
Supernus Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Trokendi XR: | Supernus |
| Migraine | XADAGO |
| Epilepsy | MYOBLOC |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Regulatory Approval | In December, the company resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations (OFF episodes) in Parkinson’s Disease (PD). |
| 2021 | Acquisitions/Mergers/Takeovers | In November, the company completed the acquisition of Adamas Pharmaceuticals, Inc. |
| 2021 | Contracts/Agreements | In April, the company secured an FDA approval Qelbree for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients. |
Competitor Comparison
| Key Parameters | Supernus Pharmaceuticals Inc | Glenmark Pharmaceuticals Ltd | Vanda Pharmaceuticals Inc | Acorda Therapeutics Inc | Sage Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | India | United States of America | United States of America | United States of America |
| City | Rockville | Mumbai | Washington | Pearl River | Cambridge |
| State/Province | Maryland | - | WashingtonD.C. | New York | Massachusetts |
| No. of Employees | 612 | 15,415 | 290 | 111 | 689 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Charles W. Newhall, III | Chairman | Executive Board | 2016 | 78 |
| Jack A. Khattar | Director; President; Chief Executive Officer; Secretary | Executive Board | 2005 | 61 |
| Timothy C. Dec | Senior Vice President; Chief Financial Officer | Senior Management | 2021 | 65 |
| Jonathan Rubin, MD | Senior Vice President - Research and Development; Chief Medical Officer | Senior Management | 2021 | 61 |
| Padmanabh P. Bhatt, Ph.D. | Chief Scientific Officer; Senior Vice President - Intellectual Property | Senior Management | 2012 | 65 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward